カレントテラピー　30-4サンプル page 22/28

このページは カレントテラピー　30-4サンプル の電子ブックに掲載されている22ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
7）Dantoine T, Auriacombe S, Sarazin M, et al：Rivastigminemonotherapy and combination therapy with memantine inpatients with moderately severe Alzheimer’s disease whofailed to benefit from previous ....

7）Dantoine T, Auriacombe S, Sarazin M, et al：Rivastigminemonotherapy and combination therapy with memantine inpatients with moderately severe Alzheimer’s disease whofailed to benefit from previous cholinesterase inhibitor treatment.Int J Clin Pract 60：110-118, 20068）Farlow MR, Cummings JL：Effective pharmacologic managementof Alzheimer’s disease. Am J Med 120：388-397, 20079）Mintzer JE, Kershaw P：The efficacy of galantamine in thetreatment of Alzheimer’s disease：comparison of patientspreviously treated with acetylcholinesterase inhibitors topatients with no prior exposure. Int J Geriatr Psychiatry18：292 -297, 200310）Sadowsky CH , Dengiz A, Olin JT, et al；US38 study group：Switching from donepezil tablets to rivastigmine transdermalpatch in Alzheimer’s disease. Am J Alzheimers Dis OtherDemen 24：267-275, 200911）Tariot PN, Farlow MR, Grossberg GT, et al；MemantineStudy Group：Memantine treatment in patients with moderateto severe Alzheimer disease already receiving donepezil：arandomized controlled trial. JAMA 291：317-324, 200412）Porsteinsson AP, Grossberg GT, Mintzer J, et al；MemantineMEM - MD - 12 Study Group：Memantine treatment inpatients with mild to moderate Alzheimer’s disease alreadyreceiving a cholinesterase inhibitor：a randomized, double -blind, placebo-controlled trial. Curr Alzheimer Res 5：83-89,200813）Sobow T：Combination treatments in Alzheimer’s disease：risk and benefits. Expert Rev Neurother 10：693-702, 201014）下濱俊：開発中のAD治療薬1）AChE阻害薬とNMDA受容体拮抗薬．Prog Med 30：2133 -2136, 201015）Kihara T, Sawada H, Nakamizo T, et al：Galantamine modulatesnicotinic receptor and blocks Aβ-enhanced glutamatetoxicity. Biochem Biophys Res Commun 325：976-982, 200416）Takata K, Kitamura Y, Saeki M, et al：Galantamine -inducedamyloid-βclearance mediated via stimulation of microglialnicotinic acetylcholine receptors. J Biol Chem 285：40180 -40191, 201017）Nordberg A, Darreh -Shori T, Peskind E, et al：Differentcholinesterase inhibitor effects on CSF cholinesterases inAlzheimer patients. Curr Alzheimer Res 6：4-14, 200918）下濱俊：認知症治療薬の新たな展開．Annual Review神経，p75?84，中外医学社，東京，201219）Mangialasche F, Solomon A, Winblad B, et al：Alzheimer’sdisease：clinical trials and drug development. Lancet Neurol9：702 -716, 201072Current Therapy 2012 Vol.30 No.4356